验证 IBIS 乳腺癌风险评估器在乳腺原位癌女性中的应用。
Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.
机构信息
Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia.
出版信息
Br J Cancer. 2018 Jul;119(1):36-39. doi: 10.1038/s41416-018-0120-z. Epub 2018 Jun 21.
BACKGROUND
Management advice for women with lobular carcinoma in situ (LCIS) is hampered by the lack of accurate personalised risk estimates for subsequent invasive breast cancer (BC). Prospective validation of the only tool that estimates individual BC risk for a woman with LCIS, the International Breast Cancer Intervention Study Risk Evaluation Tool (IBIS-RET), is lacking.
METHODS
Using population-based cancer registry data for 732 women with LCIS, the calibration and discrimination accuracy of IBIS-RET Version 7.2 were assessed.
RESULTS
The mean observed 10-year risk of invasive BC was 14.1% (95% CI:11.3%-17.5%). IBIS-RET overestimated invasive BC risk (p = 0.0003) and demonstrated poor discriminatory accuracy (AUC 0.54, 95% CI: 0.48 - 0.62).
CONCLUSIONS
Clinicians should understand that IBIS-RET Version 7.2 may overestimate 10-year invasive BC risk for Australian women with LCIS. The newer IBIS-RET Version 8.0, released September 2017, includes mammographic density and may perform better, but validation is needed.
背景
由于缺乏对患有乳腺原位癌（LCIS）的女性后续浸润性乳腺癌（BC）的准确个体化风险评估，因此对患有乳腺原位癌的女性的个体 BC 风险进行评估的唯一工具——国际乳腺癌干预研究风险评估工具（IBIS-RET）的管理建议受到了阻碍。该工具缺乏前瞻性验证。
方法
利用基于人群的癌症登记数据，对 732 名患有 LCIS 的女性进行了 IBIS-RET 版本 7.2 的校准和判别准确性评估。
结果
平均观察到的 10 年浸润性 BC 风险为 14.1%（95%CI：11.3%-17.5%）。IBIS-RET 高估了浸润性 BC 风险（p=0.0003），且判别准确性较差（AUC 为 0.54，95%CI：0.48-0.62）。
结论
临床医生应了解，IBIS-RET 版本 7.2 可能高估了澳大利亚患有 LCIS 的女性 10 年浸润性 BC 风险。2017 年 9 月发布的更新版 IBIS-RET 版本 8.0 纳入了乳腺密度信息，其表现可能更好，但仍需验证。
Zotero 插件